RESOLUTIONS ADOPTED DURING THE EXTRAORDINARY GENERAL MEETING OF MEDICALGORITHMICS S.A. WITH ITS REGISTERED OFFICE IN WARSAW HELD ON NOVEMBER 18, 2026

“Resolution No. 1/11/2026
of November 18, 2026
of the Extraordinary General Meeting
Medicalgorithmics S.A. with its registered office in Warsaw
on the election of the Chairperson of the General Meeting

§ 1

The Extraordinary General Meeting of Medicalgorithmics S.A. hereby elects Mr Michał Żółtowski as the Chairperson of the General Meeting.

§ 2

The resolution shall enter into force upon its adoption.”

In a secret ballot on the above resolution, a total of 4,319,062 (four million three hundred nineteen thousand sixty-two) valid votes were cast from 4,319,062 (four million three hundred nineteen thousand sixty-two) shares, representing approximately 41.32% (forty-one point thirty-two percent) of the Company's share capital, including:
4,315,462 (four million three hundred fifteen thousand four hundred sixty-two) votes in favour,
3,600 (three thousand six hundred) votes against,
0 (zero) abstentions.

“Resolution No. 2/11/2026
of November 18, 2026
of the Extraordinary General Meeting
Medicalgorithmics S.A. with its registered office in Warsaw
on the adoption of the agenda of the General Meeting

§ 1

The Extraordinary General Meeting of Medicalgorithmics S.A. hereby adopts the following agenda of the General Meeting:

1. Opening of the General Meeting,
2. Election of the Chairperson of the General Meeting,
3. Ascertaining that the General Meeting has been duly convened and is capable of adopting resolutions,
4. Adoption of the agenda of the General Meeting,
5. Adoption of a resolution on increasing the Company's share capital through the issuance of new

Series R ordinary bearer shares by way of a rights issue (closed subscription) with the pre-emptive rights of the existing shareholders maintained, determining the record date for the exercise of pre-emptive rights, amending the Company's Articles of Association, registering the individual subscription rights (Jednostkowe Prawa Poboru) for Series R shares and the Series R shares in the securities depository, and applying for the admission and introduction of such instruments to trading on the regulated market, with the proposed record date for the exercise of pre-emptive rights being November 30, 2026,

6. Adoption of a resolution on increasing the Company's share capital through the issuance of Series S shares, excluding in full the pre-emptive rights of the existing shareholders with respect to the Series S shares, offering the Series S shares by way of a private subscription, and amending the Company's Articles of Association,
7. Adoption of resolutions regarding changes in the composition of the Company's Supervisory Board,
8. Closing of the General Meeting.

§ 2

The resolution shall enter into force upon its adoption."

In an open vote on the above resolution, a total of 4,319,062 (four million three hundred nineteen thousand sixty-two) valid votes were cast from 4,319,062 (four million three hundred nineteen thousand sixty-two) shares, representing approximately 41.32% (forty-one point thirty-two percent) of the Company's share capital, including:
4,318,562 (four million three hundred eighteen thousand five hundred sixty-two) votes in favour,
0 (zero) votes against,
500 (five hundred) abstentions.

"Resolution No. 3/11/2026
of November 18, 2026
of the Extraordinary General Meeting
Medicalgorithmics S.A. with its registered office in Warsaw
on the increase of the Company's share capital through the issuance of series R ordinary bearer shares by way of a closed subscription with the pre-emptive rights of the existing shareholders maintained, determination of the record date for pre-emptive rights, amendment of the Company's Articles of Association, registration of Individual Subscription Rights for Series R shares and Series R shares in the securities depository, and application for admission and introduction of Series R shares to trading on the regulated market

§ 1

The Extraordinary General Meeting of Medicalgorithmics S.A., with its registered office in Warsaw (the "**Company**"), acting pursuant to Article 310 § 2 and § 4 in conjunction with Article 431 § 7, Article 430 § 1, Article 431 § 1 and § 2 item 2, Article 432 § 1–3, Article 433 § 1, Article 434 and Article 436 of the

Polish Commercial Companies Code (the "**CCC**") and § 14 of the Company's Articles of Association, hereby resolves as follows:

§ 2

1. The Extraordinary General Meeting hereby increases the Company's share capital by an amount of not less than PLN 0.10 (ten groszy) and not more than PLN 104,533.90 (one hundred four thousand five hundred thirty-three zlotys and ninety groszy).
2. The share capital increase shall be effected through the issuance of no fewer than 1 (one) and no more than 1,045,339 (one million forty-five thousand three hundred thirty-nine) Series R ordinary bearer shares with a nominal value of PLN 0.10 (ten groszy) each (the "**Series R Shares**").
3. The Series R Shares shall be issued by way of a closed subscription within the meaning of Article 431 § 2 item 2 of the CCC, carried out in the form of a public offering within the meaning of Article 2(d) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC ("**Regulation 2017/1129**").
4. The Series R Shares shall be offered to the Company's shareholders entitled to subscribe for Series R Shares according to their shareholdings as at the end of the Record Date.
5. The issue price of one Series R Share shall be PLN 20.00 (twenty zlotys).
6. The Series R Shares shall be paid for exclusively with cash contributions, paid in full upon submitting a subscription for the Series R Shares.
7. The Series R Shares shall participate in dividends on the following terms:
   1) if the Series R Shares are recorded for the first time in a securities account no later than on the dividend date determined in the General Meeting's resolution regarding the distribution of profit, they shall participate in dividends starting from the profit for the preceding financial year, i.e. from January 1 of the financial year immediately preceding the year in which they were first recorded in a securities account;
   2) if the Series R Shares are recorded for the first time in a securities account after the dividend date, they shall participate in dividends starting from the profit for the financial year in which they were first recorded in a securities account, i.e. from January 1 of that financial year.

§ 3

1. November 30, 2026 is established as the record date for the Series R pre-emptive rights within the meaning of Article 432 § 2 of the CCC (the "**Record Date**").
2. Shareholders holding Company shares at the end of the Record Date shall be entitled to pre-emptive rights to subscribe for Series R Shares, whereby for each 1 (one) Company share held at the end of the Record Date, a shareholder shall be entitled to 1 (one) subscription right (the "**Individual Subscription Right**"), and 10 (ten) Individual Subscription Rights shall entitle the holder to subscribe for 1 (one) Series R Share.
3. If the number of Series R Shares allocated to a shareholder through the exercise of Individual Subscription Rights is not a whole number, the result shall be rounded down to the nearest whole number.
4. The period for exercising the Individual Subscription Rights shall be specified in the announcement

referred to in Article 434 § 1 of the CCC and, if required under applicable law, also in the relevant information document prepared in connection with the public offering of the Series R Shares.

5. Pursuant to Article 436 § 2 of the CCC, shareholders entitled to Individual Subscription Rights may submit, within the period for exercising such rights, an additional subscription for Series R Shares in a number not exceeding the maximum number of Series R Shares issued pursuant to this resolution, in the event that other shareholders do not exercise their pre-emptive rights. Series R Shares subscribed for pursuant to additional subscriptions shall be allocated proportionally to the submitted additional subscriptions.
6. Series R Shares not subscribed for through the exercise of Individual Subscription Rights or additional subscriptions may be allocated by the Management Board at its discretion, taking into account the interests of the Company, but at a price not lower than the issue price specified in § 2 section 5 of this resolution.
7. Detailed rules regarding the exercise of pre-emptive rights, submission of primary and additional subscriptions and allocation of Series R Shares shall be determined by the Management Board within the limits of this resolution, the provisions of the Commercial Companies Code, the regulations of KDPW and GPW and other regulations applicable to the issue.

§ 4

1. The Extraordinary General Meeting authorises the Management Board to undertake all factual and legal actions necessary to implement this resolution, conduct the public offering of the Series R Shares and seek the admission and introduction of the Series R Shares to trading on the regulated market operated by the Warsaw Stock Exchange ("**GPW**"), including in particular:
   1) determining the opening and closing dates of the subscription for the Series R Shares;
   2) determining detailed rules for submitting and paying for subscriptions for Series R Shares through the exercise of Individual Subscription Rights and additional subscriptions;
   3) determining detailed rules for the allocation of Series R Shares covered by additional subscriptions, taking into account the principles set out in § 3 of this resolution;
   4) determining detailed rules for allocating and subscribing for Series R Shares not subscribed for through the exercise of Individual Subscription Rights or additional subscriptions;
   5) determining the detailed timetable of the public offering of the Series R Shares, including allocation dates and dates for returning overpaid or improperly paid funds;
   6) preparing, approving and publishing the announcement referred to in Article 434 § 1 of the CCC;
   7) preparing, approving, filing or submitting to the competent authorities and making publicly available any information documents required under applicable laws in connection with the public offering of the Series R Shares and the application for their admission to trading on the regulated market;
   8) concluding an agreement with an investment firm acting as intermediary in the public offering of the Series R Shares and any other agreements necessary to conduct the offering, subject to obtaining any corporate approvals required under the Company's Articles of Association;
   9) allocating the Series R Shares in accordance with this resolution and the provisions of the Commercial Companies Code;

10) making a notarial statement regarding the amount of subscribed share capital and specifying the amount of the share capital in the Company's Articles of Association in accordance with Article 310 § 2 and § 4 in conjunction with Article 431 § 7 of the CCC;
11) undertaking any other factual and legal actions necessary to carry out the issue of the Series R Shares and implement this resolution.

2. The Extraordinary General Meeting authorises the Management Board to decide to:
   1) withdraw from conducting the public offering of the Series R Shares;
   2) suspend the public offering of the Series R Shares, whereby the Management Board may refrain from indicating a new date for resumption of the offering;
   3) amend the timetable of the public offering of the Series R Shares,

   provided that such decision is permissible under applicable laws, KDPW and GPW regulations and with due respect for the vested rights of investors.

§ 5

1. The Extraordinary General Meeting hereby authorises the Management Board to enter into one or more agreements with the National Depository for Securities ("**KDPW**") for the registration in the securities depository maintained by KDPW of: (i) the Individual Subscription Rights and (ii) the Series R Shares, and to undertake all other actions related to such registration.
2. The Extraordinary General Meeting authorises the Management Board to undertake all actions related to seeking the admission and introduction of the Series R Shares to trading on the regulated market operated by GPW.

§ 6

1. In connection with the increase of the share capital referred to in § 2 of this resolution, the Extraordinary General Meeting of the Company resolves to amend § 5 sections 1 and 2 of the Articles of Association, which shall henceforth read as follows:

   "*1. The share capital of the Company shall amount to not less than PLN 1,045,339.00 (one million forty-five thousand three hundred thirty-nine zlotys) and not more than PLN 1,149,872.80 (one million one hundred forty-nine thousand eight hundred seventy-two zlotys 80/100).*

   2. The share capital of the Company consists of not less than 10,453,390 (ten million four hundred fifty-three thousand three hundred ninety) and not more than 11,498,728 (eleven million four hundred ninety-eight thousand seven hundred twenty-eight) ordinary shares with a nominal value of PLN 0.10 (ten groszy) each, including:

   a) 1,747,200 (one million seven hundred forty-seven thousand two hundred) bearer shares of series A,
   b) 508,200 (five hundred eight thousand two hundred) bearer shares of series B,
   c) 236,926 (two hundred thirty-six thousand nine hundred twenty-six) bearer shares of series C,
   d) 929,600 (nine hundred twenty-nine thousand six hundred) bearer shares of series D,
   e) 33,600 (thirty-three thousand six hundred) bearer shares of series E,
   f) 151,000 (one hundred fifty-one thousand) bearer shares of series F,
   g) 721,303 (seven hundred twenty-one thousand three hundred three) bearer shares of series G,

h) *648,556 (six hundred forty-eight thousand five hundred fifty-six) bearer shares of series H,*

i) *995,276 (nine hundred ninety-five thousand two hundred seventy-six) bearer shares of series I,*

j) *1,194,331 (one million one hundred ninety-four thousand three hundred thirty-one) registered shares of series J,*

k) *1,433,197 (one million four hundred thirty-three thousand one hundred ninety-seven) registered shares of series K,*

l) *1,353,580 (one million three hundred fifty-three thousand five hundred eighty) registered shares of series L,*

m) *500,620 (five hundred thousand six hundred and twenty) bearer shares of series P*,

n) *not less than 1 (one) and not more than 1,045,339 (one million forty-five thousand three hundred thirty-nine) bearer shares of series R.".*

2. The final amount by which the Company's share capital is increased, within the limits specified in § 2 section 1 of this resolution, the amount of subscribed share capital and the final wording of § 5 sections 1 and 2 of the Articles of Association shall be determined by the Management Board pursuant to Article 310 § 2 and § 4 in conjunction with Article 431 § 7 of the CCC, by executing, following completion of the subscription and allocation of the Series R Shares, a notarial deed containing a statement on the amount of the subscribed share capital.

§ 7

This Resolution shall enter into force upon its adoption, provided that the share capital increase and the related amendment to the Articles of Association shall become effective upon their registration in the Register of Entrepreneurs of the National Court Register."

In an open vote on the above resolution, a total of 4,321,562 (four million three hundred twenty-one thousand five hundred sixty-two) valid votes were cast from 4,321,562 (four million three hundred twenty-one thousand five hundred sixty-two) shares, representing approximately 41.34% (forty-one point thirty-four percent) of the Company's share capital, including:
4,227,361 (four million two hundred twenty-seven thousand three hundred sixty-one) votes in favour,
94,201 (ninety-four thousand two hundred one) votes against,
0 (zero) abstentions.

"Procedural Resolution No. 4/11/2026
of November 18, 2026
of the Extraordinary General Meeting
of Medicalgorithmics S.A. with its registered office in Warsaw
on refraining from voting on the draft resolution included in item 6 of the agenda

§ 1

The General Meeting resolves to refrain from voting on the draft resolution included in item 6 of the agenda concerning the increase of the Company's share capital through the issuance of Series S shares, the complete exclusion of the existing shareholders' pre-emptive rights with respect to the Series S shares, the offering of the Series S shares by way of a private subscription, and the amendment of the Company's Articles of Association.

§ 2

The resolution shall enter into force upon its adoption."

In an open vote on the above resolution, a total of 4,317,962 (four million three hundred seventeen thousand nine hundred sixty-two) valid votes were cast from 4,317,962 (four million three hundred seventeen thousand nine hundred sixty-two) shares, representing approximately 41.31% (forty-one point thirty-one percent) of the Company's share capital, including:
3,349,559 (three million three hundred forty-nine thousand five hundred fifty-nine) votes in favour,
129,357 (one hundred twenty-nine thousand three hundred fifty-seven) votes against,
839,046 (eight hundred thirty-nine thousand forty-six) abstentions.

"Resolution No. 5/11/2026
of November 18 2026
of the Extraordinary General Meeting
of Medicalgorithmics S.A. with its registered office in Warsaw
on the appointment of a member of the Company's Supervisory Board

§ 1

Pursuant to Article 385 § 1 of the Commercial Companies Code in conjunction with § 17 sec. 2 of the Company's Articles of Association, the General Meeting of Medicalgorithmics S.A. hereby appoints Mr Przemysław Tadla to the Company's Supervisory Board.

§ 2

The resolution shall enter into force upon its adoption."

In a secret ballot on the above resolution, a total of 4,317,962 (four million three hundred seventeen thousand nine hundred sixty-two) valid votes were cast from 4,317,962 (four million three hundred seventeen thousand nine hundred sixty-two) shares, representing approximately 41.31% (forty-one point thirty-one percent) of the Company's share capital, including:
3,554,915 (three million five hundred fifty-four thousand nine hundred fifteen) votes in favour,
42,959 (forty-two thousand nine hundred fifty-nine) votes against,
720,088 (seven hundred twenty thousand eighty-eight) abstentions.

“Resolution No. 6/11/2026
of November 18 2026
of the Extraordinary General Meeting
of Medicalgorithmics S.A. with its registered office in Warsaw
on the dismissal of a member of the Company’s Supervisory Board

§ 1

Pursuant to Article 385 § 1 of the Commercial Companies Code in conjunction with § 17 sec. 2 of the Company’s Articles of Association, the General Meeting of Medicalgorithmics S.A. hereby dismisses Mr Marcin Gołębicki from membership of the Company’s Supervisory Board.

§ 2

The resolution shall enter into force upon its adoption.”

In a secret ballot on the above resolution, a total of 4,317,962 (four million three hundred seventeen thousand nine hundred sixty-two) valid votes were cast from 4,317,962 (four million three hundred seventeen thousand nine hundred sixty-two) shares, representing approximately 41.31% (forty-one point thirty-one percent) of the Company's share capital, including:
2,948,101 (two million nine hundred forty-eight thousand one hundred one) votes in favour,
500,995 (five hundred thousand nine hundred ninety-five) votes against,
868,866 (eight hundred sixty-eight thousand eight hundred sixty-six) abstentions.